# RELATIVITY-123 (NCT05328908)

> A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab-relatlimab FDC
- Indication: later-line MSS metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05328908
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Bristol-Myers Squibb
- Conditions: Colorectal Neoplasms
- Interventions: Nivolumab-relatlimab FDC; Regorafenib; TAS-102
- Enrollment: 769
- Primary outcome: Overall Survival (OS)

## Indexed commentary on RELATIVITY-123 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=relativity-123-nct05328908